.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson
Accenture
Dow
Moodys
Boehringer Ingelheim
US Department of Justice
Cerilliant
Deloitte
Merck

Generated: September 21, 2017

DrugPatentWatch Database Preview

Viiv Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for VIIV HLTHCARE, and when can generic versions of VIIV HLTHCARE drugs launch?

VIIV HLTHCARE has eighteen approved drugs.

There are fourteen US patents protecting VIIV HLTHCARE drugs.

There are seven hundred and forty-four patent family members on VIIV HLTHCARE drugs in sixty-eight countries.

Summary for Applicant: Viiv Hlthcare

Patents:14
Tradenames:11
Ingredients:11
NDAs:18
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare
TIVICAY
dolutegravir sodium
TABLET;ORAL204790-001Aug 12, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
TIVICAY
dolutegravir sodium
TABLET;ORAL204790-001Aug 12, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-004Nov 4, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Viiv Hlthcare
TRIUMEQ
abacavir sulfate; dolutegravir sodium; lamivudine
TABLET;ORAL205551-001Aug 22, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Viiv Hlthcare
TIVICAY
dolutegravir sodium
TABLET;ORAL204790-003Jun 9, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
EPIVIR
lamivudine
TABLET;ORAL020564-001Nov 17, 1995ABRXYesNo► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
TIVICAY
dolutegravir sodium
TABLET;ORAL204790-002Jun 9, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
RETROVIR
zidovudine
CAPSULE;ORAL019655-001Mar 19, 1987ABRXYesYes► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
TRIZIVIR
abacavir sulfate; lamivudine; zidovudine
TABLET;ORAL021205-001Nov 14, 2000ABRXYesYes► Subscribe► SubscribeY► Subscribe
Viiv Hlthcare
ZIAGEN
abacavir sulfate
TABLET;ORAL020977-001Dec 17, 1998ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Viiv Hlthcare

Paragraph IV activity for VIIV HLTHCARE drugs

Drugname Dosage Strength Tradename Submissiondate
abacavir
Oral Solution20 mg/ml
ZIAGEN
12/27/2012
fosamprenavir calcium
Tablets700 mg
LEXIVA
1/18/2012
lamivudine
Oral Solution10 mg/mL
EPIVIR
11/22/2011
maraviroc
Tablets150 mg and 300 mg
SELZENTRY
8/8/2011
abacavir sulfate, lamivudine and zidovudine
Tablets300 mg/150 mg/300 mg
TRIZIVIR
3/22/2011
abacavir sulfate
Tablets300 mg
ZIAGEN
1/28/2009
lamivudine
Tablets150 mg and 300 mg
EPIVIR
10/16/2007
abacavir sulfate and lamivudine
Tablets600 mg/300 mg
EPZICOM
9/27/2007
lamivudine and zidovudine
Tablets150 mg/300 mg
COMBIVIR
6/26/2007

Non-Orange Book Patents for Viiv Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,410,103(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent► Subscribe
8,778,943Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-.alpha- .]pyrrolo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamides► Subscribe
8,754,214Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates► Subscribe
7,108,864Tablet formation► Subscribe
6,503,905 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives► Subscribe
7,592,368Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors► Subscribe
9,051,337Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-a]pyrr- olo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamides► Subscribe
6,838,474 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors► Subscribe
8,624,023Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates► Subscribe
8,188,271Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Viiv Hlthcare Drugs

Country Document Number Estimated Expiration
Poland190505► Subscribe
South Africa200708970► Subscribe
United Kingdom9506490► Subscribe
Estonia03996► Subscribe
Eurasian Patent Organization004311► Subscribe
Guatemala200100096► Subscribe
TunisiaSN99255► Subscribe
Netherlands300339► Subscribe
Norway327892► Subscribe
Japan3437553► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Viiv Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00338Netherlands► SubscribePRODUCT NAME: MARAVIROC, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918
C/GB05/027United Kingdom► SubscribeSPC/GB05/027: 20050922, EXPIRES: 20191216
C0022France► SubscribePRODUCT NAME: ABACAVIR SULFATE; LAMIVUDINE; REGISTRATION NO/DATE: EU/1/04/298/001 20041217
/2005Austria► SubscribePRODUCT NAME: KOMBINATION, UMFASSEND ABACAVIR BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES ESTERS ODER SOLVAT DAVON UND LAMIVUDIN BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES; REGISTRATION NO/DATE: EU/1/04/298/001, EU/1/04/298/002 20041217
2014021Lithuania► SubscribePRODUCT NAME: DOLUTEGRAVIRUM NATRICUM; REGISTRATION NO/DATE: EU/1/13/892/001, 2014 01 16 EU/1/13/892/002 20140116
/2008Austria► SubscribePRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
C016/2005Ireland► SubscribeSPC016/2005: 20060407, EXPIRES: 20191216
426Luxembourg► Subscribe91426, EXPIRES: 20190712
C008/2008Ireland► SubscribeSPC008/2008: 20081105, EXPIRES: 20220917
2008004Lithuania► SubscribePRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010 20070918
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Citi
Merck
Novartis
US Army
Boehringer Ingelheim
Farmers Insurance
Healthtrust
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot